Cancer found in the post-operative remnant stomach includes both newly developed cancer after surgery for benigndisease (PRC) and metachronous multiple cancer (MRC). Differences in the carcinogenic pathway between PRC and MRC have been suspected from clinical studies. However, no study has demonstrated the difference in molecular alteration between these diseases. P16 is inactivated predominantly by epigenetic change, rather than genetic alteration. We analyzed the methylation status and protein expression of the p16 gene in cancers of the remnant stomach. Eleven lesions of PRC, 24 lesions of MRC and corresponding non-cancerous tissue, as well as 13 primary gastric cancer (PC) lesions were examined. DNA was extracted by the micro-dissection method from paraffin-embedded surgical specimens. The methylation status of the promoter CpG island of the p16 gene was examined by using a methylation-specific polymerase chain reaction technique. To detect protein expression, immunohistochemical staining was employed. p16 promoter hypermethylation was observed more often in remnant gastric cancer than in PC. A significantly more frequent hypermethylation in the p16 gene was found in PRC (64%) than in MRC (21%) or PC (23%). Moreover, a significant correlation was found between p16 promoter hypermethylation and diminishment of protein expression in cancers of the remnant stomach. Silencing of the p16 gene by methylation of its promoter CpG island was suggested as a unique molecular mechanism in the carcinogenesis of PRC compared with MRC or PC.
Introduction:
Helicobacter pylori eradication remains a problematic issue. We are in an urgent need for finding a
treatment regimen that achieves eradication at a low cost and less side effect. Recent published results showing a high rate
of resistance and with clarithromycin-based treatment regimens. The aim of the study was to compare moxifloxacin therapy
and classic clarithromycin triple therapy in H. pylori eradication.
Methods:
This was a pilot study that enrolled 60 patients with helicobacter pylori associated gastritis. Diagnosis was done
by assessment of H. pylori Ag in the stool. The patients were randomly assigned to receive either moxifloxacin based therapy (Group A), or clarithromycin based therapy (Group B) for two weeks. We stopped the treatment for another two weeks
then reevaluation for cure was done.
Results:
90 % of patients had negative H. pylori Ag in the stool after 2 weeks of stoppage of the treatment in group A versus
66.7 % in Group B. None of the patients in both groups had major side effects.
Conclusion:
Moxifloxacin-based therapy showed higher eradication power and less resistance when compared to clarithromycin triple therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.